No­var­tis builds can­cer pipeline with a new plat­form/drug buy­out, bag­ging Ad­vanced Ac­cel­er­a­tor Ap­pli­ca­tions for $3.9B

No­var­tis has just bought it­self a new can­cer ther­a­py as well as a new tech plat­form for $3.9 bil­lion in cash, bag­ging the French biotech Ad­vanced Ac­cel­er­a­tor Ap­pli­ca­tions $AAAP.

The phar­ma gi­ant is pay­ing a mod­est 44% pre­mi­um over the biotech’s mar­ket val­u­a­tion from Sep­tem­ber 28, when Bloomberg re­port­ed that No­var­tis was kick­ing the tires and run­ning the num­bers on the biotech’s drug Lu­tathera (177Lu-DOTATATE).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER